|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106 USD | -1.21% |
|
-1.51% | -3.72% |
| Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
| Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
Abbott Laboratories reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 9,964 million compared to USD 9,747 million a year ago. Net income was USD 1,225 million compared to USD 1,318 million a year ago.
Diluted earnings per share from continuing operations was USD 0.7 compared to USD 0.75 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.72% | 186B | |
| -2.60% | 107B | |
| -3.79% | 67.44B | |
| +2.66% | 50.03B | |
| +16.39% | 47.81B | |
| +4.79% | 41.03B | |
| +1.38% | 26.85B | |
| +1.52% | 25.82B | |
| -1.17% | 25.01B | |
| +16.55% | 24.74B |
ABBOTT LABORATORIES 
